Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung

Yung Hung Luo, Chieh Hung Wu, Chu Yun Huang, Chih Wei Wu, Wen Shuo Wu, Yu Chin Lee, Jacqueline Whang-Peng, Yuh Min Chen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: Epidermal growth factor receptor (EGFR) mutations are frequent in pulmonary adenocarcinoma patients. The association between tumor EGFR mutation and characteristics of brain metastasis (BM) is still unclear. Methods: We retrospectively reviewed pulmonary adenocarcinoma patients with and without BMs, and characteristics of BM to analyze the association between tumor EGFR mutation and characteristics of BM. Results: Of 374 cases, 239 had EGFR mutations; 69 had BM at initial diagnosis, and 82 with BMs after treatment. All eligible patients received EGFR-tyrosine kinase inhibitors treatment. Older patients (≥70 years old) were less likely to have BMs than younger patients (25.8% vs 48%, P < 0.001). Patients with higher N stage had higher proportion of BMs (P = 0.006). Patients with exon 19 deletion were more likely to have BMs than those without EGFR mutation (48.1% vs 34.1%, P = 0.021). Patients with exon 19 deletion didn't have significantly higher chance of BMs at initial diagnosis but had higher chance to develop BM after treatment than those without EGFR mutation (35.6% vs 21.2%, P = 0.019). Patients with exon 19 deletion survived longer than those without EGFR mutation (1-year survival rate 95.8% vs 78.7%, P = 0.003). Thus, longer survival may lead to higher proportion of BM occurrence in patients with exon 19 deletion than those without EGFR mutation. Conclusions: In pulmonary adenocarcinoma, there is no significant difference in frequency of BMs at initial diagnosis between patients with EGFR mutation and wild type. However, after treatment, patients with EGFR mutations are significantly more likely to develop BM.

Original languageEnglish
Pages (from-to)e440-e448
JournalAsia-Pacific Journal of Clinical Oncology
Volume13
Issue number5
DOIs
Publication statusPublished - Oct 1 2017

Fingerprint

Epidermal Growth Factor Receptor
Neoplasm Metastasis
Mutation
Brain
Neoplasms
Exons
Adenocarcinoma of lung
Therapeutics
Protein-Tyrosine Kinases
Survival Rate
Survival

Keywords

  • adenocarcinoma of the lungs
  • brain metastasis
  • exon 19 deletion
  • lymph node
  • tumor epidermal growth factor receptor

ASJC Scopus subject areas

  • Oncology

Cite this

Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung. / Luo, Yung Hung; Wu, Chieh Hung; Huang, Chu Yun; Wu, Chih Wei; Wu, Wen Shuo; Lee, Yu Chin; Whang-Peng, Jacqueline; Chen, Yuh Min.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 13, No. 5, 01.10.2017, p. e440-e448.

Research output: Contribution to journalArticle

Luo, Yung Hung ; Wu, Chieh Hung ; Huang, Chu Yun ; Wu, Chih Wei ; Wu, Wen Shuo ; Lee, Yu Chin ; Whang-Peng, Jacqueline ; Chen, Yuh Min. / Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung. In: Asia-Pacific Journal of Clinical Oncology. 2017 ; Vol. 13, No. 5. pp. e440-e448.
@article{65d59801b17a4f6fae8ba94e3c6c5581,
title = "Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung",
abstract = "Aim: Epidermal growth factor receptor (EGFR) mutations are frequent in pulmonary adenocarcinoma patients. The association between tumor EGFR mutation and characteristics of brain metastasis (BM) is still unclear. Methods: We retrospectively reviewed pulmonary adenocarcinoma patients with and without BMs, and characteristics of BM to analyze the association between tumor EGFR mutation and characteristics of BM. Results: Of 374 cases, 239 had EGFR mutations; 69 had BM at initial diagnosis, and 82 with BMs after treatment. All eligible patients received EGFR-tyrosine kinase inhibitors treatment. Older patients (≥70 years old) were less likely to have BMs than younger patients (25.8{\%} vs 48{\%}, P < 0.001). Patients with higher N stage had higher proportion of BMs (P = 0.006). Patients with exon 19 deletion were more likely to have BMs than those without EGFR mutation (48.1{\%} vs 34.1{\%}, P = 0.021). Patients with exon 19 deletion didn't have significantly higher chance of BMs at initial diagnosis but had higher chance to develop BM after treatment than those without EGFR mutation (35.6{\%} vs 21.2{\%}, P = 0.019). Patients with exon 19 deletion survived longer than those without EGFR mutation (1-year survival rate 95.8{\%} vs 78.7{\%}, P = 0.003). Thus, longer survival may lead to higher proportion of BM occurrence in patients with exon 19 deletion than those without EGFR mutation. Conclusions: In pulmonary adenocarcinoma, there is no significant difference in frequency of BMs at initial diagnosis between patients with EGFR mutation and wild type. However, after treatment, patients with EGFR mutations are significantly more likely to develop BM.",
keywords = "adenocarcinoma of the lungs, brain metastasis, exon 19 deletion, lymph node, tumor epidermal growth factor receptor",
author = "Luo, {Yung Hung} and Wu, {Chieh Hung} and Huang, {Chu Yun} and Wu, {Chih Wei} and Wu, {Wen Shuo} and Lee, {Yu Chin} and Jacqueline Whang-Peng and Chen, {Yuh Min}",
year = "2017",
month = "10",
day = "1",
doi = "10.1111/ajco.12576",
language = "English",
volume = "13",
pages = "e440--e448",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung

AU - Luo, Yung Hung

AU - Wu, Chieh Hung

AU - Huang, Chu Yun

AU - Wu, Chih Wei

AU - Wu, Wen Shuo

AU - Lee, Yu Chin

AU - Whang-Peng, Jacqueline

AU - Chen, Yuh Min

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Aim: Epidermal growth factor receptor (EGFR) mutations are frequent in pulmonary adenocarcinoma patients. The association between tumor EGFR mutation and characteristics of brain metastasis (BM) is still unclear. Methods: We retrospectively reviewed pulmonary adenocarcinoma patients with and without BMs, and characteristics of BM to analyze the association between tumor EGFR mutation and characteristics of BM. Results: Of 374 cases, 239 had EGFR mutations; 69 had BM at initial diagnosis, and 82 with BMs after treatment. All eligible patients received EGFR-tyrosine kinase inhibitors treatment. Older patients (≥70 years old) were less likely to have BMs than younger patients (25.8% vs 48%, P < 0.001). Patients with higher N stage had higher proportion of BMs (P = 0.006). Patients with exon 19 deletion were more likely to have BMs than those without EGFR mutation (48.1% vs 34.1%, P = 0.021). Patients with exon 19 deletion didn't have significantly higher chance of BMs at initial diagnosis but had higher chance to develop BM after treatment than those without EGFR mutation (35.6% vs 21.2%, P = 0.019). Patients with exon 19 deletion survived longer than those without EGFR mutation (1-year survival rate 95.8% vs 78.7%, P = 0.003). Thus, longer survival may lead to higher proportion of BM occurrence in patients with exon 19 deletion than those without EGFR mutation. Conclusions: In pulmonary adenocarcinoma, there is no significant difference in frequency of BMs at initial diagnosis between patients with EGFR mutation and wild type. However, after treatment, patients with EGFR mutations are significantly more likely to develop BM.

AB - Aim: Epidermal growth factor receptor (EGFR) mutations are frequent in pulmonary adenocarcinoma patients. The association between tumor EGFR mutation and characteristics of brain metastasis (BM) is still unclear. Methods: We retrospectively reviewed pulmonary adenocarcinoma patients with and without BMs, and characteristics of BM to analyze the association between tumor EGFR mutation and characteristics of BM. Results: Of 374 cases, 239 had EGFR mutations; 69 had BM at initial diagnosis, and 82 with BMs after treatment. All eligible patients received EGFR-tyrosine kinase inhibitors treatment. Older patients (≥70 years old) were less likely to have BMs than younger patients (25.8% vs 48%, P < 0.001). Patients with higher N stage had higher proportion of BMs (P = 0.006). Patients with exon 19 deletion were more likely to have BMs than those without EGFR mutation (48.1% vs 34.1%, P = 0.021). Patients with exon 19 deletion didn't have significantly higher chance of BMs at initial diagnosis but had higher chance to develop BM after treatment than those without EGFR mutation (35.6% vs 21.2%, P = 0.019). Patients with exon 19 deletion survived longer than those without EGFR mutation (1-year survival rate 95.8% vs 78.7%, P = 0.003). Thus, longer survival may lead to higher proportion of BM occurrence in patients with exon 19 deletion than those without EGFR mutation. Conclusions: In pulmonary adenocarcinoma, there is no significant difference in frequency of BMs at initial diagnosis between patients with EGFR mutation and wild type. However, after treatment, patients with EGFR mutations are significantly more likely to develop BM.

KW - adenocarcinoma of the lungs

KW - brain metastasis

KW - exon 19 deletion

KW - lymph node

KW - tumor epidermal growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=84983354616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983354616&partnerID=8YFLogxK

U2 - 10.1111/ajco.12576

DO - 10.1111/ajco.12576

M3 - Article

C2 - 27550395

AN - SCOPUS:84983354616

VL - 13

SP - e440-e448

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 5

ER -